Literature DB >> 16088632

Steroid-unresponsive asthma.

Donald Y M Leung1, Joseph D Spahn, Stanley J Szefler.   

Abstract

Although most patients with chronic asthma respond to corticosteroid therapy, a small subset of asthmatics are unresponsive to corticosteroids and demonstrate persistent airway obstruction and inflammation despite treatment with high doses of systemic glucocorticoids. There are at least two types of steroid-resistant asthma. Type I steroid-resistant (SR) asthma is cytokine induced and is associated with increased expression of glucocorticoid receptor beta, a less active glucocorticoid receptor isoform. Type II SR asthma is due to low numbers of glucocorticoid receptors. An important distinction between these two types of SR asthma is that the glucocorticoid receptor defect in Type I, but not Type II, SR asthma is reversible in culture and is sustained by incubation with combination interleukin (IL)-2 and IL-4. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure as well as the use of alternative strategies to inhibit airway inflammation.

Entities:  

Year:  2002        PMID: 16088632     DOI: 10.1055/s-2002-34353

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  9 in total

Review 1.  Promise and pitfalls in animal-based asthma research: building a better mousetrap.

Authors:  David B Corry; Charles G Irvin
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  The Difficult-to-Control Asthmatic: A Systematic Approach.

Authors:  Annie V Le; Ronald A Simon
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

3.  IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids.

Authors:  Gaetano Zizzo; Philip L Cohen
Journal:  J Immunol       Date:  2013-04-17       Impact factor: 5.422

4.  TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma.

Authors:  Matthew L Stoll; Daniel H Solomon; Kerri L Batra; Julia F Simard; Elizabeth W Karlson; Paul F Dellaripa; Michael E Weinblatt; Roberta Glass; Nancy A Shadick
Journal:  J Clin Rheumatol       Date:  2009-06       Impact factor: 3.517

5.  T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia.

Authors:  Laura K Fogli; Mark S Sundrud; Swati Goel; Sofia Bajwa; Kari Jensen; Emmanuel Derudder; Amy Sun; Maryaline Coffre; Catherine Uyttenhove; Jacques Van Snick; Marc Schmidt-Supprian; Anjana Rao; Gabriele Grunig; Joan Durbin; Stefano Casola; Stefano S Casola; Klaus Rajewsky; Sergei B Koralov
Journal:  J Immunol       Date:  2013-08-21       Impact factor: 5.422

Review 6.  Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders.

Authors:  Keven M Robinson; Michelle L Manni; Partha S Biswas; John F Alcorn
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

7.  Pharmacogenomics of pediatric asthma.

Authors:  Sarika Gupta; Shally Awasthi
Journal:  Indian J Hum Genet       Date:  2010-09

Review 8.  The glucocorticoid receptor: a revisited target for toxins.

Authors:  Jeanette I Webster Marketon; Esther M Sternberg
Journal:  Toxins (Basel)       Date:  2010-06-09       Impact factor: 4.546

9.  The complex relationship between inflammation and lung function in severe asthma.

Authors:  M L Manni; J B Trudeau; E V Scheller; S Mandalapu; M M Elloso; J K Kolls; S E Wenzel; J F Alcorn
Journal:  Mucosal Immunol       Date:  2014-02-19       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.